{
    "organizations": [],
    "uuid": "2416f60c1ae3b23de524c0b98242dec41590d14a",
    "author": "",
    "url": "https://www.reuters.com/article/brief-spero-therapeutics-appoints-david/brief-spero-therapeutics-appoints-david-melnick-as-chief-medical-officer-idUSASB0BZQB",
    "ord_in_thread": 0,
    "title": "BRIEF-Spero Therapeutics Appoints David Melnick As Chief Medical Officer",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 37 PM / Updated 8 minutes ago BRIEF-Spero Therapeutics Appoints David Melnick As Chief Medical Officer Reuters Staff \nJan 4 (Reuters) - Spero Therapeutics Inc: \n* SPERO THERAPEUTICS APPOINTS DAVID MELNICK, M.D., AS CHIEF MEDICAL OFFICER \n* SPERO THERAPEUTICS INC - ‍PRIOR TO JOINING CO, MELNICK SERVED AS VICE PRESIDENT OF CLINICAL DEVELOPMENT FOR ANTI-INFECTIVES AT ALLERGAN SINCE 2015​ Source text for Eikon: Further company coverage:",
    "published": "2018-01-04T14:35:00.000+02:00",
    "crawled": "2018-01-04T14:47:38.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "therapeutic",
        "appoints",
        "david",
        "melnick",
        "chief",
        "medical",
        "officer",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "spero",
        "therapeutic",
        "inc",
        "spero",
        "therapeutic",
        "appoints",
        "david",
        "melnick",
        "chief",
        "medical",
        "officer",
        "spero",
        "therapeutic",
        "inc",
        "joining",
        "co",
        "melnick",
        "served",
        "vice",
        "president",
        "clinical",
        "development",
        "allergan",
        "since",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}